Abstract
Prolactinomas are a rare subset of brain tumors in pediatrics. We report a child with a prolactin secreting macroadenoma which was refractory to initial treatment with a dopamine antagonist. Given the location of her tumor she was ineligible for surgical resection. Temozolomide (200 mg/m2×5 days each month) was administered with a dramatic and prolonged response in tumor size, prolactin level, and symptoms, with no side effects from treatment. We demonstrate the benefit of temozolomide in the treatment of a pediatric patient with prolactinoma.
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s)played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
References
1. Liu Y, Yao Y, Xing B, Lian W, Deng K, et al. Prolactinomas in children under 14. Clinical presentation and long-term follow-up. Childs Nerv Syst 2015;31:909–16.10.1007/s00381-015-2679-5Search in Google Scholar
2. Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011;96:273–88.10.1210/jc.2010-1692Search in Google Scholar
3. Yeh PJ, Chen JW. Pituitary tumors: surgical and medical management. Surg Oncol 1997;6:67–92.10.1016/S0960-7404(97)00008-XSearch in Google Scholar
4. Fadul CE, Kominsky AL, Meyer LP, Kingman LS, Kinlaw WB, et al. Long-term response of pituitary carcinoma to temozolomide. Report of two cases. J Neurosurg 2006;105:621–6.10.3171/jns.2006.105.4.621Search in Google Scholar PubMed
5. Syro LV, Ortiz LD, Scheithauer BW, Lloyd R, Lau Q, et al. Treatment of pituitary neoplasms with temozolomide: a review. Cancer 2011;117:454–62.10.1002/cncr.25413Search in Google Scholar PubMed
6. Casanueva FF, Molitch ME, Schlechte JA, Abs R, Bonert V, et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf) 2006;65:265–73.10.1111/j.1365-2265.2006.02562.xSearch in Google Scholar PubMed
7. Komotar RJ, Starke RM, Raper DM, Anand VK, Schwartz TH. Endoscopic endonasal compared with microscopic transsphenoidal and open transcranial resection of giant pituitary adenomas. Pituitary 2012;15:150–9.10.1007/s11102-011-0359-3Search in Google Scholar PubMed
8. Bishop AJ, Greenfield B, Mahajan A, Paulino AC, Okcu MF, et al. Whitehead and DR Grosshans. Proton beam therapy versus conformal photon radiation therapy for childhood craniopharyngioma: multi-institutional analysis of outcomes, cyst dynamics, and toxicity. Int J Radiat Oncol Biol Phys 2014;90:354–61.10.1016/j.ijrobp.2014.05.051Search in Google Scholar PubMed PubMed Central
9. Nicholson HS, Kretschmar CS, Krailo M, Bernstein M, Kadota R, et al. Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children’s Oncology Group. Cancer 2007;110:1542–50.10.1002/cncr.22961Search in Google Scholar PubMed
©2016 Walter de Gruyter GmbH, Berlin/Boston
